Haematological malignancies: at the forefront of immunotherapeutic innovation
Open accessThe DOI matches its Crossref record; 216 of the 216 references it cites were found in a registry or an index.
Abstract
The recent successes of cancer immunotherapies have stimulated interest in the potential widespread application of these approaches; haematological malignancies have provided both initial proofs of concept and an informative testing ground for various immune-based therapeutics. The immune-cell origin of many of the blood malignancies provides a unique opportunity both to understand the mechanisms of cancer immune responsiveness and immune evasion, and to exploit these mechanisms for therapeutic purposes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“It has recently emerged that factors beyond tumor genomics influence cancer development and therapeutic responses (4–7), including host factors such as the gastrointestinal (gut) microbiome (8–10).”
From Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients (2018) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
Knight, D. A., Ngiow, S. F., Li, M., Parmenter, T., Mok, S., Cass, A., Haynes, N. M., Kinross, K., Yagita, H., Koya, R. C., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66236 · Cited by 269
RetractedCD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
Kohrt, H. E., Houot, R., Goldstein, M. J., Weiskopf, K., Alizadeh, A. A., Brody, J., Müller, A., Pachynski, R., Czerwinski, D., Coutre, S., et al. (2011) · Blood · doi:10.1182/blood-2010-08-301945 · Cited by 205
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., et al. (2002) · Science · doi:10.1126/science.1068440 · Cited by 3,380
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Innate or adaptive immunity? The example of natural killer cells
Vivier, E., Raulet, D. H., Moretta, A., Caligiuri, M. A., Zitvogel, L., Lanier, L. L., Yokoyama, W. M., & Ugolini, S. (2011) · Science · doi:10.1126/science.1198687 · Cited by 2,824
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Palumbo, A., & Anderson, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,326
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164
Raje, N., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,163
Vaccine Adjuvants: Putting Innate Immunity to Work
Coffman, R. L., Sher, A., & Seder, R. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.002 · Cited by 1,924
Miller, J. S., Soignier, Y., Panoskaltsis-Mortari, A., McNearney, S. A., Yun, G. H., Fautsch, S. K., McKenna, D., Le, C., Defor, T. E., Burns, L. J., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2974 · Cited by 1,903
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306220 · Cited by 1,685
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L., et al. (2011) · Science · doi:10.1126/science.1198443 · Cited by 1,672
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
Davis, R. E., Ngo, V. N., Lenz, G., Tolar, P., Young, R. M., Romesser, P. B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., et al. (2010) · Nature · doi:10.1038/nature08638 · Cited by 1,643
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., et al. (1988) · Nature · doi:10.1038/332083a0 · Cited by 1,633
Kochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P. T., Carpenter, R. O., Stetler-Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2025 · Cited by 1,595
Combining immunotherapy and targeted therapies in cancer treatment
Vanneman, M., & Dranoff, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3237 · Cited by 1,586
Reshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,562
Younes, A., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., Ramchandren, R., Bartlett, N. L., Cheson, B. D., de Vos, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0410 · Cited by 1,529
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Goede, V., Fischer, K., Busch, R., Engelke, A., Eichhorst, B., Wendtner, C. M., Chagorova, T., de la Serna, J., Dilhuydy, M.-S., Illmer, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313984 · Cited by 1,518
Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472
Replacing the complementarity-determining regions in a human antibody with those from a mouse
Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S., & Winter, G. (1986) · Nature · doi:10.1038/321522a0 · Cited by 1,406
Green, M. R., Monti, S., Rodig, S. J., Juszczynski, P., Currie, T., O'Donnell, E., Chapuy, B., Takeyama, K., Neuberg, D., Golub, T. R., et al. (2010) · Blood · doi:10.1182/blood-2010-05-282780 · Cited by 1,305
Weng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300
Topp, M. S., Gökbuget, N., Stein, A. S., Zugmaier, G., O'Brien, S., Bargou, R. C., Dombret, H., Fielding, A. K., Heffner, L., Larson, R. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71170-2 · Cited by 1,269
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Akbay, E. A., Koyama, S., Carretero, J., Altabef, A., Tchaicha, J. H., Christensen, C. L., Mikse, O. R., Cherniack, A. D., Beauchamp, E. M., Pugh, T. J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0310 · Cited by 1,231
Bates, G. J., Fox, S. B., Han, C., Leek, R. D., Garcia, J. F., Harris, A. L., & Banham, A. H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9584 · Cited by 1,200
Pro, B., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., Matous, J., Ramchandren, R., Fanale, M., Connors, J. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0402 · Cited by 997
Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody
Miller, R. A., Maloney, D. G., Warnke, R., & Levy, R. (1982) · New England Journal of Medicine · doi:10.1056/nejm198203043060906 · Cited by 985
Dendritic cell immunotherapy: mapping the way
Figdor, C. G., de Vries, I. J. M., Lesterhuis, W. J., & Melief, C. J. M. (2004) · Nature Medicine · doi:10.1038/nm1039 · Cited by 945
Zitvogel, L., Galluzzi, L., Smyth, M. J., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.014 · Cited by 870
Dubovsky, J. A., Beckwith, K. A., Natarajan, G., Woyach, J. A., Jaglowski, S., Zhong, Y., Hessler, J. D., Liu, T.-M., Chang, B. Y., Larkin, K. M., et al. (2013) · Blood · doi:10.1182/blood-2013-06-507947 · Cited by 810
Hussell, T., Isaacson, P. G., Spencer, J., & Crabtree, J. E. (1993) · The Lancet · doi:10.1016/0140-6736(93)91408-e · Cited by 783
Heslop, H. E., Slobod, K. S., Pule, M. A., Hale, G. A., Rousseau, A., Smith, C. A., Bollard, C. M., Liu, H., Wu, M.-F., Rochester, R. J., et al. (2010) · Blood · doi:10.1182/blood-2009-08-239186 · Cited by 780
Davis, T. A., Grillo-López, A. J., White, C. A., McLaughlin, P., Czuczman, M. S., Link, B. K., Maloney, D. G., Weaver, R. L., Rosenberg, J., & Levy, R. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3135 · Cited by 687
Molldrem, J. J., Lee, P. P., Wang, C., Felio, K., Kantarjian, H. M., Champlin, R. E., & Davis, M. M. (2000) · Nature Medicine · doi:10.1038/79526 · Cited by 672
Topp, M. S., Gökbuget, N., Zugmaier, G., Klappers, P., Stelljes, M., Neumann, S., Viardot, A., Marks, R., Diedrich, H., Faul, C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.3247 · Cited by 658
Rubnitz, J. E., Inaba, H., Ribeiro, R. C., Pounds, S., Rooney, B., Bell, T., Pui, C.-H., & Leung, W. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.4590 · Cited by 649
Antibody-modified T cells: CARs take the front seat for hematologic malignancies
Maus, M. V., Grupp, S. A., Porter, D. L., & June, C. H. (2014) · Blood · doi:10.1182/blood-2013-11-492231 · Cited by 616
MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers
Steidl, C., Shah, S. P., Woolcock, B. W., Rui, L., Kawahara, M., Farinha, P., Johnson, N. A., Zhao, Y., Telenius, A., Neriah, S. B., et al. (2011) · Nature · doi:10.1038/nature09754 · Cited by 615
Burger, J. A., Tsukada, N., Burger, M., Zvaifler, N. J., Dell'Aquila, M., & Kipps, T. J. (2000) · Blood · doi:10.1182/blood.v96.8.2655 · Cited by 607
Ramsay, A. G., Johnson, A. J., Lee, A. M., Gorgün, G., Le Dieu, R., Blum, W., Byrd, J. C., & Gribben, J. G. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35017 · Cited by 600
Bendandi, M., Gocke, C. D., Kobrin, C. B., Benko, F. A., Sternas, L. A., Pennington, R., Watson, T. M., Reynolds, C. W., Gause, B. L., Duffey, P. L., et al. (1999) · Nature Medicine · doi:10.1038/13928 · Cited by 594
Cooley, S., Weisdorf, D. J., Guethlein, L. A., Klein, J. P., Wang, T., Le, C. T., Marsh, S. G. E., Geraghty, D., Spellman, S., Haagenson, M. D., et al. (2010) · Blood · doi:10.1182/blood-2010-05-283051 · Cited by 591
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
Wierda, W. G., Kipps, T. J., Mayer, J., Stilgenbauer, S., Williams, C. D., Hellmann, A., Robak, T., Furman, R. R., Hillmen, P., Trneny, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3187 · Cited by 590
Cancer Immunotherapy Comes of Age
Topalian, S. L., Weiner, G. J., & Pardoll, D. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0899 · Cited by 586
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity
Park, S., Jiang, Z., Mortenson, E. D., Deng, L., Radkevich-Brown, O., Yang, X., Sattar, H., Wang, Y., Brown, N. K., Greene, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.06.014 · Cited by 577
Doll, S. R. (1980) · Cancer · doi:10.1002/1097-0142(19800515)45:10<2475::aid-cncr2820451004>3.0.co;2-6 · Cited by 565
The tumour microenvironment in B cell lymphomas
Scott, D. W., & Gascoyne, R. D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3774 · Cited by 552
Antibody Therapeutics in Cancer
Sliwkowski, M. X., & Mellman, I. (2013) · Science · doi:10.1126/science.1241145 · Cited by 543
Oka, Y., Tsuboi, A., Taguchi, T., Osaki, T., Kyo, T., Nakajima, H., Elisseeva, O. A., Oji, Y., Kawakami, M., Ikegame, K., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405884101 · Cited by 531
Westin, J. R., Chu, F., Zhang, M., Fayad, L. E., Kwak, L. W., Fowler, N., Romaguera, J., Hagemeister, F., Fanale, M., Samaniego, F., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70551-5 · Cited by 529
Riches, J. C., Davies, J. K., McClanahan, F., Fatah, R., Iqbal, S., Agrawal, S., Ramsay, A. G., & Gribben, J. G. (2013) · Blood · doi:10.1182/blood-2012-09-457531 · Cited by 529
Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling
Minden, M. D.-V., Übelhart, R., Schneider, D., Wossning, T., Bach, M. P., Buchner, M., Hofmann, D., Surova, E., Follo, M., Köhler, F., et al. (2012) · Nature · doi:10.1038/nature11309 · Cited by 504
Carreras, J., Lopez-Guillermo, A., Fox, B. C., Colomo, L., Martinez, A., Roncador, G., Montserrat, E., Campo, E., & Banham, A. H. (2006) · Blood · doi:10.1182/blood-2006-04-018218 · Cited by 503
Bollard, C. M., Gottschalk, S., Torrano, V., Diouf, O., Ku, S., Hazrat, Y., Carrum, G., Ramos, C., Fayad, L., Shpall, E. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.5304 · Cited by 503
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
Brody, J. D., Ai, W. Z., Czerwinski, D. K., Torchia, J. A., Levy, M., Advani, R. H., Kim, Y. H., Hoppe, R. T., Knox, S. J., Shin, L. K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.9793 · Cited by 487
Topp, M. S., Gökbuget, N., Zugmaier, G., Degenhard, E., Goebeler, M.-E., Klinger, M., Neumann, S. A., Horst, H. A., Raff, T., Viardot, A., et al. (2012) · Blood · doi:10.1182/blood-2012-07-441030 · Cited by 474
Tai, Y.-T., Dillon, M., Song, W., Leiba, M., Li, X.-F., Burger, P., Lee, A. I., Podar, K., Hideshima, T., Rice, A. G., et al. (2008) · Blood · doi:10.1182/blood-2007-08-107292 · Cited by 473
Hsu, K. C., Keever-Taylor, C. A., Wilton, A., Pinto, C., Heller, G., Arkun, K., O'Reilly, R. J., Horowitz, M. M., & Dupont, B. (2005) · Blood · doi:10.1182/blood-2004-12-4825 · Cited by 473
Clinical targeting of the TNF and TNFR superfamilies
Croft, M., Benedict, C. A., & Ware, C. F. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3930 · Cited by 456
Bulliard, Y., Jolicoeur, R., Windman, M., Rue, S. M., Ettenberg, S., Knee, D. A., Wilson, N. S., Dranoff, G., & Brogdon, J. L. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130573 · Cited by 446
Armand, P., Nagler, A., Weller, E. A., Devine, S. M., Avigan, D. E., Chen, Y.-B., Kaminski, M. S., Holland, H. K., Winter, J. N., Mason, J. R., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.3685 · Cited by 440
Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma
Cheson, B. D., & Leonard, J. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708875 · Cited by 438
Bachanova, V., Cooley, S., Defor, T. E., Verneris, M. R., Zhang, B., McKenna, D. H., Curtsinger, J., Panoskaltsis-Mortari, A., Lewis, D., Hippen, K., et al. (2014) · Blood · doi:10.1182/blood-2013-10-532531 · Cited by 435
HLA-C–Dependent Prevention of Leukemia Relapse by Donor Activating KIR2DS1
Venstrom, J. M., Pittari, G., Gooley, T. A., Chewning, J. H., Spellman, S., Haagenson, M., Gallagher, M. M., Malkki, M., Petersdorf, E., Dupont, B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200503 · Cited by 429
CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help
French, R. R., Chan, H. T. C., Tutt, A. L., & Glennie, M. J. (1999) · Nature Medicine · doi:10.1038/8426 · Cited by 426
Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia
Zenatti, P. P., Ribeiro, D., Li, W., Zuurbier, L., Silva, M. C., Paganin, M., Tritapoe, J., Hixon, J. A., Silveira, A. B., Cardoso, B. A., et al. (2011) · Nature Genetics · doi:10.1038/ng.924 · Cited by 416
Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1
Gao, L., Bellantuono, I., Elsässer, A., Marley, S. B., Gordon, M. Y., Goldman, J. M., & Stauss, H. J. (2000) · Blood · doi:10.1182/blood.v95.7.2198 · Cited by 408
Sotomayor, E. M., Borrello, I., Tubb, E., Rattis, F.-M., Bien, H., Lu, Z., Fein, S., Schoenberger, S., & Levitsky, H. I. (1999) · Nature Medicine · doi:10.1038/10503 · Cited by 407
A unique cell surface antigen identifying lymphoid malignancies of B cell origin.
Nadler, L. M., Ritz, J., Hardy, R., Pesando, J. M., Schlossman, S. F., & Stashenko, P. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110005 · Cited by 399
Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia
Preudhomme, C., Guilhot, J., Nicolini, F. E., Guerci-Bresler, A., Rigal-Huguet, F., Maloisel, F., Coiteux, V., Gardembas, M., Berthou, C., Vekhoff, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1004095 · Cited by 392
Galustian, C., Meyer, B., Labarthe, M.-C., Dredge, K., Klaschka, D., Henry, J., Todryk, S., Chen, R., Muller, G., Stirling, D., et al. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0620-4 · Cited by 391
Van Tendeloo, V. F., Van de Velde, A., Van Driessche, A., Cools, N., Anguille, S., Ladell, K., Gostick, E., Vermeulen, K., Pieters, K., Nijs, G., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008051107 · Cited by 377
Aberrant Overexpression of the Wilms Tumor Gene (WT1) in Human Leukemia
Inoue, K., Ogawa, H., Sonoda, Y., Kimura, T., Sakabe, H., Oka, Y., Miyake, S., Tamaki, H., Oji, Y., Yamagami, T., et al. (1997) · Blood · doi:10.1182/blood.v89.4.1405 · Cited by 371
Bashey, A., Medina, B., Corringham, S., Pasek, M., Carrier, E., Vrooman, L., Lowy, I., Solomon, S. R., Morris, L. E., Holland, H. K., et al. (2009) · Blood · doi:10.1182/blood-2008-07-168468 · Cited by 364
Bone marrow as a priming site for T-cell responses to blood-borne antigen
Feuerer, M., Beckhove, P., Garbi, N., Mahnke, Y., Limmer, A., Hommel, M., Hämmerling, G. J., Kyewski, B., Hamann, A., Umansky, V., et al. (2003) · Nature Medicine · doi:10.1038/nm914 · Cited by 353
Prabhala, R. H., Pelluru, D., Fulciniti, M., Prabhala, H. K., Nanjappa, P., Song, W., Pai, C., Amin, S., Tai, Y.-T., Richardson, P. G., et al. (2010) · Blood · doi:10.1182/blood-2009-10-246660 · Cited by 351
Expression of the Wilms' tumor gene (WT1) in human leukemias.
Miwa, H., Beran, M., & Saunders, G. F. (1992) · PubMed · Cited by 349
Zonder, J. A., Mohrbacher, A. F., Singhal, S., van Rhee, F., Bensinger, W. I., Ding, H., Fry, J., Afar, D. E. H., & Singhal, A. K. (2012) · Blood · doi:10.1182/blood-2011-06-360552 · Cited by 342
Rezvani, K., Yong, A. S. M., Mielke, S., Savani, B. N., Musse, L., Superata, J., Jafarpour, B., Boss, C., & Barrett, A. J. (2008) · Blood · doi:10.1182/blood-2007-08-108241 · Cited by 341
T cell immune reconstitution following lymphodepletion
Williams, K. M., Hakim, F. T., & Gress, R. E. (2007) · Seminars in Immunology · doi:10.1016/j.smim.2007.10.004 · Cited by 340
CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia
Wierda, W. G., Cantwell, M. J., Woods, S. J., Rassenti, L. Z., Prussak, C. E., & Kipps, T. J. (2000) · Blood · doi:10.1182/blood.v96.9.2917 · Cited by 340
Rakhra, K., Bachireddy, P., Zabuawala, T., Zeiser, R., Xu, L., Kopelman, A., Fan, A. C., Yang, Q., Braunstein, L., Crosby, E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.002 · Cited by 339
Self-citationAnsell, S. M., Hurvitz, S. A., Koenig, P. A., LaPlant, B. R., Kabat, B. F., Fernando, D., Habermann, T. M., Inwards, D. J., Verma, M., Yamada, R., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1339 · Cited by 332
Burger, J. A., Quiroga, M. P., Hartmann, E., Bürkle, A., Wierda, W. G., Keating, M. J., & Rosenwald, A. (2009) · Blood · doi:10.1182/blood-2008-07-170415 · Cited by 330
Molldrem, J., Dermime, S., Parker, K., Jiang, Y., Mavroudis, D., Hensel, N., Fukushima, P., & Barrett, A. (1996) · Blood · doi:10.1182/blood.v88.7.2450.bloodjournal8872450 · Cited by 325
Hakim, F. T., Cepeda, R., Kaimei, S., Mackall, C. L., McAtee, N., Zujewski, J., Cowan, K., & Gress, R. E. (1997) · Blood · doi:10.1182/blood.v90.9.3789 · Cited by 323
Yang, Z.-Z., Grote, D. M., Ziesmer, S. C., Niki, T., Hirashima, M., Novak, A. J., Witzig, T. E., & Ansell, S. M. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59806 · Cited by 309
Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia
Rajasagi, M., Shukla, S. A., Fritsch, E. F., Keskin, D. B., DeLuca, D., Carmona, E., Zhang, W., Sougnez, C., Cibulskis, K., Sidney, J., et al. (2014) · Blood · doi:10.1182/blood-2014-04-567933 · Cited by 309
Self-citationPatton, D. T., Garden, O. A., Pearce, W. P., Clough, L. E., Monk, C. R., Leung, E., Rowan, W. C., Sancho, S., Walker, L. S. K., Vanhaesebroeck, B., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.10.6598 · Cited by 303
Keilholz, U., Letsch, A., Busse, A., Asemissen, A. M., Bauer, S., Blau, I. W., Hofmann, W.-K., Uharek, L., Thiel, E., & Scheibenbogen, C. (2009) · Blood · doi:10.1182/blood-2009-02-202598 · Cited by 300
Jenq, R. R., & van den Brink, M. R. M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2804 · Cited by 299
Carreras, J., Lopez-Guillermo, A., Roncador, G., Villamor, N., Colomo, L., Martinez, A., Hamoudi, R., Howat, W. J., Montserrat, E., & Campo, E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0513 · Cited by 296
Lonial, S., Vij, R., Harousseau, J.-L., Facon, T., Moreau, P., Mazumder, A., Kaufman, J. L., Leleu, X., Tsao, L. C., Westland, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.2649 · Cited by 296
Barata, J. T., Silva, A., Brandao, J. G., Nadler, L. M., Cardoso, A. A., & Boussiotis, V. A. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040789 · Cited by 284
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission
Vey, N., Bourhis, J.-H., Boissel, N., Bordessoule, D., Prebet, T., Charbonnier, A., Etienne, A., Andre, P., Romagne, F., Benson, D., et al. (2012) · Blood · doi:10.1182/blood-2012-06-437558 · Cited by 278
Advances in targeting cell surface signalling molecules for immune modulation
Yao, S., Zhu, Y., & Chen, L. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3877 · Cited by 267
Bocchia, M., Gentili, S., Abruzzese, E., Fanelli, A., Iuliano, F., Tabilio, A., Amabile, M., Forconi, F., Gozzetti, A., Raspadori, D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17945-8 · Cited by 247
Schuster, S. J., Neelapu, S. S., Gause, B. L., Janik, J. E., Muggia, F. M., Gockerman, J. P., Winter, J. N., Flowers, C. R., Nikcevich, D. A., Sotomayor, E. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.3005 · Cited by 245
Benson, D. M., Hofmeister, C. C., Padmanabhan, S., Suvannasankha, A., Jagannath, S., Abonour, R., Bakan, C., Andre, P., Efebera, Y., Tiollier, J., et al. (2012) · Blood · doi:10.1182/blood-2012-06-438028 · Cited by 244
Choudhury, A., Liang, J. C., Thomas, E. K., Flores-Romo, L., Xie, Q. S., Agusala, K., Sutaria, S., Sinha, I., Champlin, R. E., & Claxton, D. F. (1999) · Blood · doi:10.1182/blood.v93.3.780 · Cited by 239
Ocio, E. M., Richardson, P. G., Rajkumar, S. V., Palumbo, A., Mateos, M. V., Orlowski, R., Kumar, S., Usmani, S., Roodman, D., Niesvizky, R., et al. (2014) · Leukemia · doi:10.1038/leu.2013.350 · Cited by 233
Prince, H. M., Duvic, M., Martin, A., Sterry, W., Assaf, C., Sun, Y., Straus, D., Acosta, M., & Negro-Vilar, A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2386 · Cited by 233
Rosenblatt, J., Vasir, B., Uhl, L., Blotta, S., MacNamara, C., Somaiya, P., Wu, Z., Joyce, R., Levine, J. D., Dombagoda, D., et al. (2011) · Blood · doi:10.1182/blood-2010-04-277137 · Cited by 228
Riemersma, S. A., Jordanova, E. S., Schop, R. F. J., Philippo, K., Looijenga, L. H. J., Schuuring, E., & Kluin, P. M. (2000) · Blood · doi:10.1182/blood.v96.10.3569 · Cited by 227
Bagnara, D., Kaufman, M. S., Calissano, C., Marsilio, S., Patten, P. E. M., Simone, R., Chum, P., Yan, X.-J., Allen, S. L., Kolitz, J. E., et al. (2011) · Blood · doi:10.1182/blood-2010-12-324210 · Cited by 221
Lee, A. M., Clear, A. J., Calaminici, M., Davies, A. J., Jordan, S., MacDougall, F., Matthews, J., Norton, A. J., Gribben, J. G., Lister, T. A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4642 · Cited by 220
Schmitt, M., Schmitt, A., Rojewski, M. T., Chen, J., Giannopoulos, K., Fei, F., Yu, Y., Götz, M., Heyduk, M., Ritter, G., et al. (2008) · Blood · doi:10.1182/blood-2007-07-099366 · Cited by 212
A novel role of IL-17–producing lymphocytes in mediating lytic bone disease in multiple myeloma
Noonan, K., Marchionni, L., Anderson, J., Pardoll, D., Roodman, G. D., & Borrello, I. (2010) · Blood · doi:10.1182/blood-2010-05-283895 · Cited by 210
CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies
Beers, S. A., Chan, C. H. T., French, R. R., Cragg, M. S., & Glennie, M. J. (2010) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.01.001 · Cited by 209
Molldrem, J. J., Lee, P. P., Kant, S., Wieder, E., Jiang, W., Lu, S., Wang, C., & Davis, M. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16398 · Cited by 209
A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia
Cathcart, K., Pinilla-Ibarz, J., Korontsvit, T., Schwartz, J., Zakhaleva, V., Papadopoulos, E. B., & Scheinberg, D. A. (2004) · Blood · doi:10.1182/blood-2003-03-0954 · Cited by 208
Rosenblatt, J., Avivi, I., Vasir, B., Uhl, L., Munshi, N. C., Katz, T., Dey, B. R., Somaiya, P., Mills, H., Campigotto, F., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0282 · Cited by 206
Greiner, J., Schmitt, M., Li, L., Giannopoulos, K., Bosch, K., Schmitt, A., Dohner, K., Schlenk, R. F., Pollack, J. R., Dohner, H., et al. (2006) · Blood · doi:10.1182/blood-2006-01-023127 · Cited by 205
Spisek, R., Kukreja, A., Chen, L.-C., Matthews, P., Mazumder, A., Vesole, D., Jagannath, S., Zebroski, H. A., Simpson, A. J. G., Ritter, G., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062387 · Cited by 199
Regulation of mature T cell homeostasis
Surh, C. D., & Sprent, J. (2005) · Seminars in Immunology · doi:10.1016/j.smim.2005.02.007 · Cited by 191
HLA-Binding Properties of Tumor Neoepitopes in Humans
Fritsch, E. F., Rajasagi, M., Ott, P. A., Brusic, V., Hacohen, N., & Wu, C. J. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0227 · Cited by 190
Self-citationAdvani, R., Forero-Torres, A., Furman, R. R., Rosenblatt, J. D., Younes, A., Ren, H., Harrop, K., Whiting, N., & Drachman, J. G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3017 · Cited by 188
The role of B7 family molecules in hematologic malignancy
Greaves, P., & Gribben, J. G. (2013) · Blood · doi:10.1182/blood-2012-10-385591 · Cited by 187
Laszlo, G. S., Gudgeon, C. J., Harrington, K. H., Dell’Aringa, J., Newhall, K. J., Means, G. D., Sinclair, A. M., Kischel, R., Frankel, S. R., & Walter, R. B. (2014) · Blood · doi:10.1182/blood-2013-09-527044 · Cited by 173
Rezvani, K., Yong, A. S. M., Savani, B. N., Mielke, S., Keyvanfar, K., Gostick, E., Price, D. A., Douek, D. C., & Barrett, A. J. (2007) · Blood · doi:10.1182/blood-2007-03-076844 · Cited by 168
Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen
Cardoso, A., Schultze, J., Boussiotis, V., Freeman, G., Seamon, M., Laszlo, S., Billet, A., Sallan, S., Gribben, J., & Nadler, L. (1996) · Blood · doi:10.1182/blood.v88.1.41.41 · Cited by 167
Richter, J., Neparidze, N., Zhang, L., Nair, S., Monesmith, T., Sundaram, R., Miesowicz, F., Dhodapkar, K. M., & Dhodapkar, M. V. (2013) · Blood · doi:10.1182/blood-2012-06-435503 · Cited by 164
Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells
Greaves, P., Clear, A., Owen, A., Iqbal, S., Lee, A., Matthews, J., Wilson, A., Calaminici, M., & Gribben, J. G. (2013) · Blood · doi:10.1182/blood-2013-06-508044 · Cited by 161
Guilloton, F., Caron, G., Ménard, C., Pangault, C., Amé-Thomas, P., Dulong, J., De Vos, J., Rossille, D., Henry, C., Lamy, T., et al. (2012) · Blood · doi:10.1182/blood-2011-08-370908 · Cited by 159
Maslak, P. G., Dao, T., Krug, L. M., Chanel, S., Korontsvit, T., Zakhaleva, V., Zhang, R., Wolchok, J. D., Yuan, J., Pinilla-Ibarz, J., et al. (2010) · Blood · doi:10.1182/blood-2009-10-250993 · Cited by 154
Moskowitz, C. H., Ribrag, V., Michot, J.-M., Martinelli, G., Zinzani, P. L., Gutierrez, M., De Maeyer, G., Jacob, A. G., Giallella, K., Weimer Anderson, J., et al. (2014) · Blood · doi:10.1182/blood.v124.21.290.290 · Cited by 154
Greaves, P., Clear, A. J., Coutinho, R., Wilson, A., Matthews, J., Owen, A., Shanyinde, M., Lister, T. A., Calaminici, M., & Gribben, J. G. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.9881 · Cited by 150
Clinical Benefit Associated With Idiotypic Vaccination in Patients With Follicular Lymphoma
Inogés, S., Rodrı́guez-Calvillo, M., Zabalegui, N., de Cerio, A. L.-D., Villanueva, H., Soria, E., Suárez, L., Rodríguez‐Caballero, A., Pastor, F., García‐Muñoz, R., et al. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj358 · Cited by 150
Oevermann, L., Michaelis, S. U., Mezger, M., Lang, P., Toporski, J., Bertaina, A., Zecca, M., Moretta, L., Locatelli, F., & Handgretinger, R. (2014) · Blood · doi:10.1182/blood-2014-03-565069 · Cited by 146
CD28-mediated regulation of multiple myeloma cell proliferation and survival
Bahlis, N. J., King, A. M., Kolonias, D. S., Carlson, L. M., Liu, H. Y., Hussein, M. A., Terebelo, H. R., Byrne, G. E., Levine, B. L., Boise, L., et al. (2007) · Blood · doi:10.1182/blood-2006-03-012542 · Cited by 145
Maier, T., Tun-Kyi, A., Tassis, A., Jungius, K.-P., Burg, G., Dummer, R., & Nestle, F. O. (2003) · Blood · doi:10.1182/blood-2002-08-2455 · Cited by 145
Balkwill, F. R., Montfort, A., & Capasso, M. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.10.007 · Cited by 138
Freedman, A. S., Neelapu, S. S., Nichols, C. R., Robertson, M. J., Djulbegović, B., Winter, J. N., Bender, J. F., Gold, D. P., Ghalie, R., Stewart, M. E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8903 · Cited by 138
Greiner, J., Ringhoffer, M., Taniguchi, M., Schmitt, A., Kirchner, D., Krähn, G. M., Heilmann, V., Gschwend, J. E., Bergmann, L., Döhner, H., et al. (2002) · Experimental Hematology · doi:10.1016/s0301-472x(02)00874-3 · Cited by 134
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma
Korde, N., Carlsten, M., Lee, M.-J., Minter, A., Tan, E., Kwok, M., Manasanch, E., Bhutani, M., Tageja, N., Roschewski, M., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.103085 · Cited by 131
Cignetti, A., Bryant, E., Allione, B., Vitale, A., Foà, R., & Cheever, M. A. (1999) · Blood · doi:10.1182/blood.v94.6.2048 · Cited by 129
Hoffman, L. M., & Gore, L. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00063 · Cited by 129
CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia
Sivina, M., Hartmann, E., Kipps, T. J., Rassenti, L., Krupnik, D., Lerner, S., LaPushin, R., Xiao, L., Huang, X., Werner, L., et al. (2011) · Blood · doi:10.1182/blood-2010-09-307249 · Cited by 127
Lesokhin, A. M., Ansell, S. M., Armand, P. A., Scott, E. C., Halwani, A. S., Gutierrez, M. E., Millenson, M. M., Cohen, A. D., Schuster, S. J., Lebovic, D. J., et al. (2014) · Blood · doi:10.1182/blood.v124.21.291.291 · Cited by 125
How Thalidomide Works Against Cancer
Stewart, A. K. (2014) · Science · doi:10.1126/science.1249543 · Cited by 124
Oka, Y., Tsuboi, A., Murakami, M., Hirai, M., Tominaga, N., Nakajima, H., Elisseeva, O. A., Masuda, T., Nakano, A., Kawakami, M., et al. (2003) · International Journal of Hematology · doi:10.1007/bf02983241 · Cited by 124
Kim, J., Denu, R. A., Dollar, B. A., Escalante, L. E., Kuether, J. P., Callander, N. S., Asimakopoulos, F., & Hematti, P. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09154.x · Cited by 122
Nicola, M. D., Zappasodi, R., Carlo‐Stella, C., Mortarini, R., Pupa, S. M., Magni, M., Devizzi, L. F., Matteucci, P., Baldassari, P., Ravagnani, F., et al. (2008) · Blood · doi:10.1182/blood-2008-06-165654 · Cited by 122
Rezvani, K., Yong, A. S. M., Mielke, S., Jafarpour, B., Savani, B. N., Le, R., Eniafe, R. B., Musse, L., Boss, C., Kurlander, R. J., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.031674 · Cited by 122
IL-7–induced proliferation of recent thymic emigrants requires activation of the PI3K pathway
Swainson, L., Kinet, S., Mongellaz, C., Sourisseau, M., Henriques, T., & Taylor, N. (2007) · Blood · doi:10.1182/blood-2006-06-027912 · Cited by 115
Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia
Jia, L., Clear, A., Liu, F.-T., Matthews, J., Uddin, N., McCarthy, A., Hoxha, E., Durance, C., Iqbal, S., & Gribben, J. G. (2014) · Blood · doi:10.1182/blood-2013-10-529610 · Cited by 115
Spontaneous regression in non-Hodgkin's lymphoma
Gattiker, H. H., Wiltshaw, E., & Galton, D. A. G. (1980) · Cancer · Cited by 113
Rojas, J. M., Knight, K., Wang, L., & Clark, R. E. (2007) · Leukemia · doi:10.1038/sj.leu.2404858 · Cited by 112
Borrello, I., Sotomayor, E. M., Cooke, S., & Levitsky, H. I. (1999) · Human Gene Therapy · doi:10.1089/10430349950017347 · Cited by 112
Ho, V. T., Vanneman, M., Kim, H., Sasada, T., Kang, Y. J., Pasek, M., Cutler, C., Koreth, J., Alyea, E., Sarantopoulos, S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908358106 · Cited by 109
Kiaii, S., Clear, A. J., Ramsay, A. G., Davies, D., Sangaralingam, A., Lee, A., Calaminici, M., Neuberg, D. S., & Gribben, J. G. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2137 · Cited by 104
Bachireddy, P., Hainz, U., Rooney, M. S., Pozdnyakova, O., Aldridge, J., Zhang, W., Liao, X., Hodi, F. S., O'Connell, K. E., Haining, W. N., et al. (2013) · Blood · doi:10.1182/blood-2013-08-523001 · Cited by 103
Self-citationIdiotype vaccines for lymphoma: proof-of-principles and clinical trial failures
Bendandi, M. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2717 · Cited by 100
Li, L., Giannopoulos, K., Reinhardt, P., Tabarkiewicz, J., Schmitt, A., Greiner, J., Roliński, J., Hus, I., Dmoszyńska, A., Wiesneth, M., et al. (2006) · International Journal of Oncology · doi:10.3892/ijo.28.4.855 · Cited by 97
Savani, B. N., Montero, A., Kurlander, R. J., Childs, R. W., Hensel, N. F., & Barrett, A. J. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705167 · Cited by 96
Smith, B. D., Kasamon, Y. L., Kowalski, J., Gocke, C. D., Murphy, K. M., Miller, C. B., Garrett-Mayer, E. S., Tsai, H., Lu, Q., Chia, C. Y., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2046 · Cited by 95
Effect of alemtuzumab on neoplastic B cells.
Golay, J., Manganini, M., Rambaldi, A., & Introna, M. (2004) · PubMed · Cited by 93
CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma
Murray, M. E., Gavile, C. M., Nair, J. R., Koorella, C., Carlson, L. M., Buac, D., Utley, A., Chesi, M., Bergsagel, P. L., Boise, L. H., et al. (2014) · Blood · doi:10.1182/blood-2013-10-530964 · Cited by 91
Umetsu, D. T., Esserman, L. J., Donlon, T. A., DeKruyff, R. H., & Levy, R. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.144.7.2550 · Cited by 90
Hus, I., Schmitt, M. W., Tabarkiewicz, J., Radej, S., Wojas‐Krawczyk, K., Bojarska-Junak, A. A., Schmitt, A., Giannopoulos, K., Dmoszyńska, A., & Roliński, J. (2008) · Leukemia · doi:10.1038/leu.2008.29 · Cited by 90
Redfern, C. H., Guthrie, T. H., Bessudo, A., Densmore, J. J., Holman, P., Janakiraman, N., Leonard, J. P., Levy, R. L., Just, R. G., Smith, M. R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.4289 · Cited by 90
Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention
Norde, W. J., Hobo, W. A., van der Voort, R., & Dolstra, H. (2012) · Blood · doi:10.1182/blood-2012-02-412510 · Cited by 89
Induction of Tumor Immunity Following Allogeneic Stem Cell Transplantation
Wu, C. J., & Ritz, J. (2006) · Advances in immunology · doi:10.1016/s0065-2776(06)90004-2 · Cited by 88
Self-citationShanafelt, T. D., Ramsay, A. G., Zent, C. S., Leis, J. F., Tun, H. W., Call, T. G., LaPlant, B. R., Bowen, D. A., Pettinger, A. M., Jelinek, D. F., et al. (2013) · Blood · doi:10.1182/blood-2012-12-470005 · Cited by 86
Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma
Levy, R., Ganjoo, K. N., Leonard, J. P., Vose, J. M., Flinn, I. W., Ambinder, R. F., Connors, J. M., Berinstein, N. L., Belch, A. R., Bartlett, N. L., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.9273 · Cited by 85
Costello, R. T., Mallet, F., Sainty, D., Maraninchi, D., Gastaut, J.-A., & Olive, D. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199801)28:01<90::aid-immu90>3.0.co;2-5 · Cited by 81
Kuball, J. H. E., de Boer, K., Wagner, E. M., Wattad, M. A., Antunes, E., Weeratna, R. D., Vicari, A. P., Lotz, C., van Dorp, S., Hol, S., et al. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0929-7 · Cited by 80
Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells
Burkhardt, U. E., Hainz, U., Stevenson, K., Goldstein, N. R., Pasek, M., Naito, M., Wu, D., Ho, V. T., Alonso, A., Hammond, N. N., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69098 · Cited by 79
Self-citationDigel, W., Schmid, M., Heil, G., Conrad, P., Gillis, S., & Porzsolt, F. (1991) · Blood · doi:10.1182/blood.v78.3.753.753 · Cited by 75
Rousseau, R. F., Biagi, E., Dutour, A., Yvon, E. S., Brown, M. P., Lin, T. F., Mei, Z., Grilley, B., Popek, E. J., Heslop, H. E., et al. (2005) · Blood · doi:10.1182/blood-2005-03-1259 · Cited by 75
IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia
Ribeiro, D., Melão, A., & Barata, J. T. (2012) · Advances in Biological Regulation · doi:10.1016/j.jbior.2012.10.005 · Cited by 71
Spontaneous regression of chronic lymphocytic leukemia: clinical and biologic features of 9 cases
Giudice, I. D., Chiaretti, S., Tavolaro, S., Propris, M. S. D., Maggio, R., Mancini, F., Peragine, N., Santangelo, S., Marinelli, M., Mauro, F. R., et al. (2009) · Blood · doi:10.1182/blood-2008-12-196568 · Cited by 69
James, D. F., Werner, L. L., Brown, J. R., Wierda, W. G., Barrientos, J. C., Castro, J. E., Greaves, A. W., Johnson, A. J., Rassenti, L. Z., Rai, K. R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.5890 · Cited by 68
Giannopoulos, K., Li, L., Bojarska-Junak, A. A., Roliński, J., Dmoszyńska, A., Hus, I., Greiner, J., Renner, C., Döhner, H., & Schmitt, M. W. (2006) · International Journal of Oncology · doi:10.3892/ijo.29.1.95 · Cited by 67
Baur, A. S., Lutz, M. B., Schierer, S., Beltrame, L., Theiner, G., Zinser, E., Ostalecki, C., Heidkamp, G., Haendle, I., Erdmann, M., et al. (2013) · Blood · doi:10.1182/blood-2012-09-456988 · Cited by 63
Ossenkoppele, G. J., Stam, A. G. M., Westers, T. M., de Gruijl, T. D., Janssen, J. J. W. M., van de Loosdrecht, A. A., & Scheper, R. J. (2003) · Leukemia · doi:10.1038/sj.leu.2402979 · Cited by 58
Recognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells
Torelli, G., Peragine, N., Raponi, S., Pagliara, D., Propris, M. D. D., Vitale, A., Bertaina, A., Barberi, W., Moretta, L., Basso, G., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.101931 · Cited by 58
Wierda, W. G., Castro, J. E., Aguillon, R. A., Sampath, D., Jalayer, A., McMannis, J., Prussak, C. E., Keating, M. J., & Kipps, T. J. (2010) · Leukemia · doi:10.1038/leu.2010.191 · Cited by 56
Uttenthal, B. J., Martínez-Dávila, I. A., Ivey, A., Craddock, C., Chen, F. E., Virchis, A., Kottaridis, P. D., Grimwade, D. J., Khwaja, A., Stauss, H. J., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12637 · Cited by 56
Giannopoulos, K., Dmoszyńska, A., Kowal, M., Roliński, J., Gostick, E., Price, D. A., Greiner, J., Rojewski, M., Stilgenbauer, S., Döhner, H., et al. (2010) · Leukemia · doi:10.1038/leu.2010.29 · Cited by 56
At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies
Locatelli, F., Merli, P., & Rutella, S. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.0613343 · Cited by 55
Cited by
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Towards personalized, tumour-specific, therapeutic vaccines for cancer
Hu, Z., Ott, P. A., & Wu, C. J. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.131 · Cited by 1,067
Self-citationThe interaction of innate immune and adaptive immune system
Wang, R., Lan, C., Benlagha, K., Camara, N. O. S., Miller, H., Kubo, M., Heegaard, S., Lee, P., Yang, L., Forsman, H., et al. (2024) · MedComm · doi:10.1002/mco2.714 · Cited by 305
“168 In the innate immune system, tumor-associated macrophages (TAMs) play an important role in tumor suppression.”
BackgroundThe Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
Moreno, L., Perez, C., Zabaleta, A., Manrique, I., Alignani, D., Ajona, D., Blanco, L., Lasa, M., Maiso, P., Rodriguez, I., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1597 · Cited by 221
“Growing knowledge about tumor and immune cell biology led to continuous development of immunotherapies against each of the four major nodes of vulnerability in the cancer–immune relationship: direct targeting of surface antigens; boosting of numbers and functioning of immune effectors; activating tumor antigen-specifi…”
BackgroundImmunogenomic Landscape of Hematological Malignancies
Dufva, O., Pölönen, P., Brück, O., Keränen, M. A. I., Klievink, J., Mehtonen, J., Huuhtanen, J., Kumar, A., Malani, D., Siitonen, S., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.002 · Cited by 190
Metadata
- Authors
- Bachireddy, P., Burkhardt, U. E., Rajasagi, M., & Wu, C. J.
- Affiliations
- Broad Institute (US)
- Dana-Farber Cancer Institute (US)
- Corresponding author
- Wu, Catherine J.
- Venue
- Nature Reviews Cancer
- Published
- 2015-03-19
- Volume
- 15
- Issue
- 4
- Pages
- 201-215
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC4511812
- OpenAlex
- W2083691419
- Cited by
- 85
- References
- 215
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 9 · 2023: 4 · 2022: 2 · 2021: 8 · 2020: 8 · 2019: 7 · 2018: 4 · 2017: 11 · 2016: 11 · 2015: 7
- FWCI
- 1.18
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL103532)
- National Human Genome Research Institute (U54HG003067)
- National Cancer Institute (P01CA206978, R01CA155010, T32CA009172, P30CA006516)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- hematologic malignancies, cancer immunotherapy, immune evasion, cancer immune response, immune checkpoint inhibitors, adoptive immunotherapy
- MeSH terms
- Animals, Humans, Immunotherapy, Hematologic Neoplasms, Cancer Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.